Key Market Indicator:
F&G: 23
25.437,00 NASDAQ · 47.695,00 DOW · 6.818,20 S&P · 4.222,77 Gold · 62,24 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
DE000A1EWVY8
Filter zurücksetzen
© EQS Newswire
27.03.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon berichtet über erfolgreiches Geschäftsjahr 2024 mit starken operativen Fortschritten und kontinuierlichem Ausbau der Marktposition
Article
News Preview
  Pressemitteilung // 27. März 2025   Formycon berichtet über erfolgreiches Geschäftsjahr 2024 mit starken operativen Fortschritten und kontinuierlichem Ausbau der Marktposition Konzernumsatz übertrifft mit 69,7 Mio. € prognostizierte Erwartungen (55,0 Mio. € bis 65,0 Mio. €)   Konzern EBITDA mit -13,7 Mio. € ebenfalls besser als Prognose (-......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
Article
News Preview
 Press Release // March 27, 2025   Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position Group revenue exceeds forecast with €69.7 million (guidance: €55.0 million to €65.0 million)   Group EBITDA at €-13.7 million also better than expected (guidance: €-25.0 mil......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.03.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 2. Quartal 2025 bekannt
Article
News Preview
Pressemitteilung // 24. März 2025  Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 2. Quartal 2025 bekannt Planegg-Martinsried – Die Formycon AG (FWB: FYB, Prime Standard, „Formycon“) hat heute Details zur Telefonkonferenz bezüglich der Veröffentlich......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
24.03.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
Article
News Preview
 Press Release // March 24, 2025   Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025 Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today announced details of the conference call for the release of the fisca......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© EQS Newswire
03.03.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Markteinführung von FYB202/Otulfi® (ustekinumab-aauz), einem Biosimilar zu Stelara® in den USA und der Europäischen Union
Article
News Preview
Pressemitteilung // 3. März 2025  Markteinführung von FYB202/Otulfi® (ustekinumab-aauz), einem Biosimilar zu Stelara® in den USA und der Europäischen Union FYB202/Otulfi® ist ab sofort in den USA und der Europäischen Union in subkutaner und intravenöser Formulierung erhältlich Behandlungsumstellung auf Otulfi® wird durch vergleichbare Wirksamkei......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.03.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
Article
News Preview
Press Release // March 3, 2025   FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous formulations in the United States and the European Union Patient transition to Otulfi® supported by comparable effic......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon erhält Zulassung in Großbritannien für FYB203 (Aflibercept), ein Biosimilar zu Eylea®, unter dem Markennamen AHZANTIVE®
Article
News Preview
Pressemitteilung // 25. Februar 2025  Formycon erhält Zulassung in Großbritannien für FYB203 (Aflibercept), ein Biosimilar zu Eylea®, unter dem Markennamen AHZANTIVE® FYB203 (Aflibercept) in Großbritannien zur Behandlung der neovaskulären altersbedingten Makuladegeneration (nAMD) sowie weiterer schwerer Netzhauterkrankungen zugelassen Britische ......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Article
News Preview
Press Release // February 25, 2025   Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases UK market authorization......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
Article
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 24.02.2025 / 11:25 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certai......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Article
News Preview
 Press Release // February 20, 2025   Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin   Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) will present an overview of the comparative data of the ustekinumab biosimilar FYB202 at this year's Congress of the European Croh......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon präsentiert klinische Daten zu Ustekinumab-Biosimilar FYB202 auf dem ECCO-Kongress in Berlin
Article
News Preview
Pressemitteilung // 20. Februar 2025   Formycon präsentiert klinische Daten zu Ustekinumab-Biosimilar FYB202 auf dem ECCO-Kongress in Berlin   Planegg-Martinsried - Die Formycon AG (FWB: FYB, Prime Standard) wird auf dem diesjährigen Kongress der European Crohn’s and Colitis Organisation (ECCO), der vom 19.02.2025 bis 22.02.2025 in Berlin stattfi......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon AG informiert über jüngste Entwicklungen in verschiedenen Biosimilar-Projekten und lädt zur Telefonkonferenz ein
Article
News Preview
Pressemitteilung // 17. Februar 2025  Formycon AG informiert über jüngste Entwicklungen in verschiedenen Biosimilar-Projekten und lädt zur Telefonkonferenz ein Formycon setzt FYB206-Entwicklung ohne Phase-III-Studie fort und nimmt damit Vorreiterrolle unter Pembrolizumab-Biosimilar-Entwicklern ein; Investitionsersparnisse belaufen sich voraussic......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
17.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Article
News Preview
Press Release // February 17, 2025 Formycon AG informs about recent developments in various biosimilar projects and invites to conference call   Formycon continues FYB206 development without Phase III trial and thus takes pioneering role among pembrolizumab biosimilar developers; investment savings expected to amount to a high double-digit millio......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon gibt Entscheidung zu Phase-III-Studie von FYB206 bekannt und informiert über potenziellen Anpassungsbedarf bei der Bewertung von FYB202 und FYB201
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 Formycon gibt Entscheidung zu Phase-III-Studie von FYB206 bekannt und informiert über potenziellen Anpassungsbedarf bei der Bewertung von FYB202 und FYB201 Formycon stellt Phase-III-Studie (Lotus) für FYB206 nach positivem Feedback der U.S. Food and Drug Ad......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 Formycon terminates Phase III study ("Lotus") for FYB206 following positive feedback from the U.S. Food and Drug A......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
Article
News Preview
Press Release // February 05, 2025   Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region   Planegg-Martinsried, Germany – Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of FYB203/AHZANTIVE®1 (aflibercept......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.02.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Lotus Pharmaceutical wird strategischer Vermarktungspartner für Formycons Eylea®-Biosimilar FYB203/AHZANTIVE® in der Asien-Pazifik-Region
Article
News Preview
Pressemitteilung // 5. Februar 2025  Lotus Pharmaceutical wird strategischer Vermarktungspartner für Formycons Eylea®-Biosimilar FYB203/AHZANTIVE® in der Asien-Pazifik-Region   Planegg-Martinsried – Klinge Biopharma GmbH („Klinge”), Lizenznehmer und exklusiver Inhaber der weltweiten Vermarktungsrechte für FYB203/AHZANTIVE®1 (Aflibercept), Formyc......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
Article
News Preview
Press Release // January 20, 2025 Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® FYB203 (aflibercept) approved for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases AHZANTIVE® and Baiama® offer patients treat......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon erhält EU-Zulassung für FYB203 (Aflibercept), ein Biosimilar zu Eylea®, unter den Markennamen AHZANTIVE® und Baiama®
Article
News Preview
Pressemitteilung // 20. Januar 2025 Formycon erhält EU-Zulassung für FYB203 (Aflibercept), ein Biosimilar zu Eylea®, unter den Markennamen AHZANTIVE® und Baiama® FYB203 (Aflibercept) zur Behandlung von neovaskulärer altersbedingter Makuladegeneration (nAMD) sowie mehreren weiteren schweren Netzhauterkrankungen zugelassen AHZANTIVE® und Baiama® b......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Article
News Preview
Press Release // January 15, 2025 Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi®received MHRA approval for both subcutaneous and intravenous formulations, to treat serious inflammatory diseases UK approval follows the series of successful approvals by the FDA, the European Co......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi geben die Zulassung von FYB202/Otulfi® (ustekinumab), einem Biosimilar zu Stelara®, durch die britische MHRA bekannt
Article
News Preview
Pressemitteilung // 15. Januar 2025 Formycon und Fresenius Kabi geben die Zulassung von FYB202/Otulfi® (ustekinumab), einem Biosimilar zu Stelara®, durch die britische MHRA bekannt Otulfi® hat die MHRA-Zulassung für subkutane und intravenöse Formulierungen zur Behandlung schwerer entzündlicher Erkrankungen erhalten Die Zulassung im Vereinigten K......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
Article
News Preview
Presse Release // January 13, 2025   Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel Planegg-Martinsried, Germany – Klinge Biopharma GmbH (Klinge), the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimila......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Teva wird strategischer Vermarktungspartner für Formycons Biosimilar-Kandidat FYB203 (Eylea®/ Aflibercept) in weiten Teilen Europas und Israel
Article
News Preview
Pressemitteilung // 13. Januar 2025   Teva wird strategischer Vermarktungspartner für Formycons Biosimilar-Kandidat FYB203 (Eylea®/ Aflibercept) in weiten Teilen Europas und Israel   Planegg-Martinsried – Die Klinge Biopharma GmbH (Klinge), Lizenznehmer und exklusiver Inhaber der weltweiten Vermarktungsrechte für FYB203, Formycons Biosimilar-Kand......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon wird in den TecDAX der Deutschen Börse aufgenommen
Article
News Preview
Pressemitteilung // 09. Januar 2025   Formycon wird in den TecDAX der Deutschen Börse aufgenommen Formycon gehört künftig zu den 30 gelisteten Top-Technologiewerten Uplisting in den Prime Standard, Aufstieg in den SDAX und erfolgreiche Geschäftsentwicklung fördern die Attraktivität der Aktie Aufnahme in den TecDAX ab 13. Januar 2025 wirksam Pla......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon included in TecDAX Index of Deutsche Börse
Article
News Preview
Press Release // January 9, 2025   Formycon included in TecDAX Index of Deutsche Börse Formycon to join the ranks of the 30 leading listed technology companies Uplisting to the Prime Standard, inclusion in the SDAX, and robust business development further enhance the stock’s appeal Entry into the TecDAX becomes effective as of January 13, 2025 ......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi Canada erhalten Zulassung von Health Canada für FYB202/Otulfi® (Ustekinumab), ein Biosimilar zu Stelara®
Article
News Preview
Pressemitteilung // 08. Januar 2025 Formycon und Fresenius Kabi Canada erhalten Zulassung von Health Canada für FYB202/Otulfi® (Ustekinumab), ein Biosimilar zu Stelara® Otulfi® wurde von Health Canada für subkutane und intravenöse Formulierungen zur Behandlung schwerer entzündlicher Erkrankungen zugelassen Health Canada schließt sich der FDA un......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Article
News Preview
Press Release // January 8, 2025 Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi® approved by Health Canada for both subcutaneous and intravenous formulations to treat serious inflammatory diseases Health Canada joins the FDA and the European Commission in gra......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.12.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
Article
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 11.12.2024 / 16:25 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cer......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.12.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region
Article
News Preview
Presse Release // December 09, 2024   MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the commercialization of FYB202, F......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.12.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
MS Pharma wird Kommerzialisierungspartner für FYB202 / Ustekinumab in der MENA-Region
Article
News Preview
Pressemitteilung // 09. Dezember 2024   MS Pharma wird Kommerzialisierungspartner für FYB202 / Ustekinumab in der MENA-Region Planegg-Martinsried, Amman, Jordanien – Die Formycon AG (FWB: FYB, Prime Standard, "Formycon" oder "Gesellschaft") und MS Pharma geben gemeinsam bekannt, dass sie eine Lizenz- und Liefervereinbarung für die Vermarktung von......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon joins the SDAX of the German Stock Exchange
Article
News Preview
Press Release // December 5, 2024 Formycon joins the SDAX of the German Stock Exchange Formycon shares will be part of the DAX index family, ranking among the 70 largest German companies below the MDAX Enhanced share attractiveness following recent uplisting to the Prime Standard Formycon shares to be included in the index effective as of Decem......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon steigt in den SDAX der Deutschen Börse auf
Article
News Preview
Pressemitteilung // 05. Dezember 2024 Formycon steigt in den SDAX der Deutschen Börse auf Formycon-Aktie gehört künftig zur DAX-Indexfamilie und zu den 70 größten deutschen Unternehmen unterhalb des MDAX Attraktivität der Aktie steigt nach kürzlich erfolgtem Uplisting in den Prime Standard Aufnahme in den Auswahlindex ab 23. Dezember 2024 wirks......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes
Article
News Preview
Press Release // November 28, 2024   Formycon reports nine-month results for 2024 and continues growth trajectory with further operational success Excellent third quarter with product approvals for FYB202 in the key markets USA and Europe Keytruda® biosimilar candidate FYB206 starts clinical development program (phase I and phase III study) Dev......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon berichtet Neunmonatsergebnis 2024 und setzt Wachstumskurs mit weiteren operativen Erfolgen fort
Article
News Preview
Pressemitteilung // 28. November 2024   Formycon berichtet Neunmonatsergebnis 2024 und setzt Wachstumskurs mit weiteren operativen Erfolgen fort Hervorragendes drittes Quartal mit Produktzulassungen für FYB202 in den Schlüsselmärkten USA und Europa Keytruda®-Biosimilar-Kandidat FYB206 startet klinisches Entwicklungsprogramm (Phase I und Phase I......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
Article
News Preview
Press Release // November 19, 2024 Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, „Formycon“) invites to the conference call and webcast for the publication of the nine-month results 2024 on November 28, 2024.......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon lädt zum Earnings-Call für das Neunmonatsergebnis 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
Article
News Preview
Pressemitteilung // 19. November 2024 Formycon lädt zum Earnings-Call für das Neunmonatsergebnis 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt  Planegg-Martinsried - Die Formycon AG (FWB: FYB, „Formycon“) lädt zur Telefonkonferenz und zum Webcast zur Veröffentlichung des Neunmonatsergebnisses 2024 am 28. November 20......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
Article
News Preview
Press Release // November 18, 2024   Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of FYB203 for the treatment of Neovascular Age-Related ......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon erhält positive CHMP-Empfehlung für FYB203 (Aflibercept), einen Biosimilar-Kandidaten für Eylea®, unter den Markennamen AHZANTIVE® und Baiama®
Article
News Preview
Pressemitteilung // 18. November 2024   Formycon erhält positive CHMP-Empfehlung für FYB203 (Aflibercept), einen Biosimilar-Kandidaten für Eylea®, unter den Markennamen AHZANTIVE® und Baiama® Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) empfiehlt die Zulassung von FYB203 zur Behandlung der neovaskulären alter......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® erhält CHMP-Empfehlung der EMA
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014   Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama®erhält CHMP-Empfehlung der EMA   Planegg-Martinsried, Deutschland, 15. November 2024 – Die Formycon AG (FWB: FYB, "Formycon“) gibt bekannt, dass die Europäischen Arzneimittel-Agentur (EMA) am heutigen Tag......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014   Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA   Planegg-Martinsried, Germany, November 15, 2024 – Formycon (FSE: FYB, "Formycon“) announces that the European Medicines Agency (EMA) published today that the Co......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon verlängert Vorstandsvertrag für CEO Dr. Stefan Glombitza bis 2027 und erhält Zulassung für Handel im Prime Standard
Article
News Preview
Pressemitteilung // 11. November 2024 Formycon verlängert Vorstandsvertrag für CEO Dr. Stefan Glombitza bis 2027 und erhält Zulassung für Handel im Prime Standard Dr. Stefan Glombitza wird für drei weitere Jahre zum Vorstand (CEO) bestellt und wird Formycon durch die nächste Phase der Unternehmensentwicklung führen Formycon-Aktien erhalten Zula......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
Article
News Preview
Press Release // November 11, 2024Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard  Dr. Stefan Glombitza has been appointed as CEO for three more years and will lead Formycon through the next phase of the company's development Formycon shares will be admitt......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
Article
News Preview
Press Release // November 04, 2024 Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange Application for admission to trading on the regulated market (Prime Standard) of the Frankfurt Stock Exchange will be submitted today Trading of Formycon shares on the Prime Standard segment is expected to start on November 12,......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon beantragt Wechsel in den Prime Standard der Frankfurter Wertpapierbörse
Article
News Preview
Pressemitteilung // 04. November 2024 Formycon beantragt Wechsel in den Prime Standard der Frankfurter Wertpapierbörse Zulassung zum Handel im regulierten Markt (Prime Standard) der Frankfurter Wertpapierbörse wird heute beantragt Formycon-Aktien werden voraussichtlich ab dem 12. November 2024 im Prime Standard der Frankfurter Wertpapierbörse ge......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.10.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon publiziert Ergebnisse der analytischen Studie zur Vergleichbarkeit des Biosimilarkandidaten FYB206 mit Keytruda® in der Fachzeitschrift Drugs in R&D
Article
News Preview
Pressemitteilung // 16. Oktober 2024   Formycon publiziert Ergebnisse der analytischen Studie zur Vergleichbarkeit des Biosimilar-Kandidaten FYB206 mit Keytruda® in der Fachzeitschrift Drugs in R&D   Ergebnisse der vergleichenden analytischen Bewertung zeigen strukturell und funktionell eine sehr hohe Similarität zwischen dem Referenzprodukt ......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.10.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
Article
News Preview
Press Release // October 16, 2024   Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D   The comparative analytical evaluation results indicate that the proposed Keytruda®-biosimilar FYB206 is structurally and functionally highly similar to the reference......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.10.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
Article
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 01.10.2024 / 17:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cer......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi erhalten FDA-Zulassung für FYB202/ OtulfiTM (Ustekinumab-aauz)
Article
News Preview
Pressemitteilung // 30. September 2024 Formycon und Fresenius Kabi erhalten FDA-Zulassung für FYB202/ OtulfiTM (Ustekinumab-aauz) Die FDA genehmigt FYB202/OtulfiTM sowohl für subkutane als auch für intravenöse Formulierungen und für alle Stelara®-Indikationen   Diese Zulassung ist die dritte erfolgreiche FDA-Zulassung für ein Biosimilar von Fo......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Article
News Preview
Press Release // September 30, 2024 Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz) OtulfiTMreceived FDA approval for both subcutaneous and intravenous formulations, to treat the same conditions as Stelara®   Approval represents the third successful FDA approval for a Formycon biosimilar, two of them in ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA erteilt Zulassung für Stelara® - Biosimilar FYB202/Otulfi™ (Ustekinumab-aauz)
Article
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014 FDA erteilt Zulassung für Stelara®- Biosimilar FYB202/Otulfi™ (Ustekinumab-aauz) Planegg-Martinsried, Deutschland, 27. September 2024 – Die Formycon AG (FWB: FYB, “Formycon“) gibt bekannt, dass die U.S. Food and Drug Administration („FDA“) heute die Zulass......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Article
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz) Planegg-Martinsried, Germany, September 27, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the U.S. Food and Drug Administration (“FDA”) today approved FYB202/OtulfiTM......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon und Fresenius Kabi erhalten Zulassung der Europäischen Kommission für FYB202/Otulfi® (Ustekinumab) zur Behandlung schwerwiegender inflammatorischer Erkrankungen
Article
News Preview
Pressemitteilung // 27. September 2024 Formycon und Fresenius Kabi erhalten Zulassung der Europäischen Kommission für FYB202/Otulfi® (Ustekinumab) zur Behandlung schwerwiegender inflammatorischer Erkrankungen FYB202/Otulfi® hat die Zulassung der Europäischen Kommission (EC) für subkutane und für intravenöse Formulierungen erhalten und bietet euro......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Article
News Preview
Press Release // September 27, 2024Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases FYB202/Otulfi® received European Commission (EC) approval for both subcutaneous and intravenous formulations, providing a high-quality treatment option for European......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon präsentiert klinische Daten zum Ustekinumab Biosimilar-Kandidaten FYB202 auf dem EADV Kongress in Amsterdam und der UEG Woche in Wien
Article
News Preview
Pressemitteilung // 17. September 2024   Formycon präsentiert klinische Daten zum Ustekinumab Biosimilar-Kandidaten FYB202 auf dem EADV Kongress in Amsterdam und der UEG Woche in Wien   Planegg-Martinsried – Die Formycon AG (FWB: FYB) wird auf dem diesjährigen Kongress der European Academy of Dermatology & Venerology (EADV), der vom 25. bis 2......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon präsentiert klinische Daten zum Ustekinumab Biosimilar-Kandidaten FYB202 auf dem EADV Kongress in Amsterdam und der UEG Woche in Wien
Article
News Preview
Pressemitteilung // 17. September 2024   Formycon präsentiert klinische Daten zum Ustekinumab Biosimilar-Kandidaten FYB202 auf dem EADV Kongress in Amsterdam und der UEG Woche in Wien   Planegg-Martinsried – Die Formycon AG (FWB: FYB) wird auf dem diesjährigen Kongress der European Academy of Dermatology & Venerology (EADV), der vom 25. bis 2......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Article
News Preview
Press Release // September 17, 2024  Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna   Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Article
News Preview
Press Release // September 17, 2024  Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna   Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.08.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
Article
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH 19.08.2024 / 14:10 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude cer......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.08.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon berichtet über starkes erstes Halbjahr mit zahlreichen Meilensteinen
Article
News Preview
Pressemitteilung // 13. August 2024 Formycon berichtet über starkes erstes Halbjahr mit zahlreichen Meilensteinen Erfolgreiche Geschäftsentwicklung geprägt durch wegweisende operative, klinische und regulatorische Meilensteine Konzernumsatz und Konzern-EBITDA entsprechen Erwartungen Operatives Ergebnis von FYB201 entwickelt sich im ersten Halb......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.08.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon reports a strong first half-year with multiple milestones achieved
Article
News Preview
Press Release // August 13, 2024 Formycon reports a strong first half-year with multiple milestones achieved Successful business development characterized by key operational, clinical, and regulatory milestones Group revenue and EBITDA in line with expectations Operating results of FYB201 in the first half of the year significantly exceeded ex......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 01.12.2025, Calendar Week 49, 335th day of the year, 30 days remaining until EoY.